Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Open-Label, Long-Term Extension Study for Oral Levosimendan (TNX-103)

Indication
Pulmonary Hypertension Associated With HFpEF

Other upcoming events for TENX

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertens
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertens
Patent ExpiryPatent/Exclusivity Expiry: IMKELDI

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Multicenter, Open-Label, Long-Term Extension Study for Oral Levosimendan (TNX-103) — TENX Phase 3 Readout | BioSniper